Modulation of the cancer cell transcriptome by culture media formulations and cell density

International Journal of Oncology

Volumn 46, Issue 5, 2015, Pages 2067-2075

  Kim, Seung Wok ^a   Kim, Sun Jin ^a   Langley, Robert R ^a   Fidler, Isaiah J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cell culture; Epithelial mesenchymal transition; Media formulation; Microarray

Indexed keywords

TRANSCRIPTOME;

ARTICLE; BREAST CANCER CELL LINE; CANCER CELL; CELL CULTURE; CELL DENSITY; CELL GROWTH; CONTROLLED STUDY; CULTURE MEDIUM; DULBECCO MODIFIED EAGLE MEDIUM; EPITHELIAL MESENCHYMAL TRANSITION; FETAL BOVINE SERUM; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENOTYPE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MINIMUM ESSENTIAL MEDIUM; PRIORITY JOURNAL; ROSWELL PARK MEMORIAL INSTITUTE MEDIUM; SERUM; TRANSCRIPTOMICS; TUMOR GENE; BREAST TUMOR; CELL COUNT; CELL CULTURE TECHNIQUE; DNA MICROARRAY; GENETICS; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL COUNT; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; GENOTYPE; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTOME;

EID: 84925426005     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.2930     Document Type: Article

References (28)

1. Begley CG and Ellis LM: Drug development: raise standards for preclinical cancer research. Nature 483: 531-533, 2012.
2. Prinz F, Schlange T and Asadullah K: Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov 10: 712, 2011.
3. Ioannidis JP: Why most published research findings are false. PLoS Med 2: e124, 2005.
4. Bissell M: Reproducibility: the risks of the replication drive. Nature 503: 333-334, 2013.
5. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002.
6. Druker BJ, Tamura S, Buchdunger E, et al: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561-566, 1996.
7. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043, 2007.
8. Gazdar AF, Gao B and Minna JD: Lung cancer cell lines: useless artifacts or invaluable tools for medical science? Lung Cancer 68: 309-318, 2010.
9. Gazdar AF, Girard L, Lockwood WW, Lam WL and Minna JD: Lung cancer cell lines as tools for biomedical discovery and research. J Natl Cancer Inst 102: 1310-1321, 2010.
10. Langley RR and Fidler IJ: The seed and soil hypothesis revisited - the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 128: 2527-2535, 2011.
11. Cascone T, Herynk MH, Xu L, et al: Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest 121: 1313-1328, 2011.
12. Kim SJ, Kim JS, Park ES, Lee JS, et al: Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia 13: 286-298, 2011.
13. Simon R, Lam A, Li MC, Ngan M, Menenzes S and Zhao Y: Analysis of gene expression data using BRB-ArrayTools. Cancer Inform 3: 11-17, 2007.
14. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
15. Eisen MB, Spellman PT, Brown PO and Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Nat Acad Sci USA 95: 14863-14868, 1998.
16. Druker BJ and Lydon NB: Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105: 3-7, 2000.
17. American Type Culture Collection Standards Development Organization Workgroup ASN- 0002: Cell line misidentification: the beginning of the end. Nat Rev Cancer 10: 441-448, 2010.
18. Barallon R, Bauer SR, Butler J, et al: Recommendation of short tandem repeat profiling for authenticating human cell lines, stem cells, and tissues. In Vitro Cell Dev Biol Anim 46: 727-732, 2010.
19. Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890, 2009.
20. Tam WL and Weinberg RA: The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 19: 1438-1449, 2013.
21. Scheel C and Weinberg RA: Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol 22: 396-403, 2012.
22. Tang L, Li H, Gou R, Cheng G, Guo Y, Fang Y and Chen F: Endothelin-1 mediated high glucose-induced epithelial-mesenchymal transition in renal tubular cells. Diabetes Res Clin Pract 104: 176-182, 2014.
23. Yu MA, Shin KS, Kim JH, et al: HGF and BMP-7 ameliorate high glucose-induced epithelial-to-mesenchymal transition of peritoneal mesothelium. J Am Soc Nephrol 20: 567-581, 2009.
24. Liu PP, Liao J, Tang ZJ, et al: Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway. Cell Death Differ 21: 124-135, 2014.
25. Kim TH, Kim HI, Soung YH, Shaw LA and Chung J: Integrin (alpha6beta4) signals through Src to increase expression of S100A4, a metastasis-promoting factor: implications for cancer cell invasion. Mol Cancer Res 7: 1605-1612, 2009.
26. Hoffmann E, Dittrich-Breiholz O, Holtmann H and Kracht M: Multiple control of interleukin-8 gene expression. J Leukoc Biol 72: 847-855, 2002.
27. Waugh DJ and Wilson C: The interleukin-8 pathway in cancer. Clin Cancer Res 14: 6735-6741, 2008.
28. Singh JK, Simões BM, Howell SJ, Farnie G and Clarke RB: Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res 15: 210, 2013.